Bahram Kazemi1,2, Farideh Tohidi3,4, Mojgan Bandehpour1, Fatemeh Yarian1. 1. Cellular and Molecular Biology Research Center, Shahid Beheshti University, Tehran, Iran. 2. Dept. of Parasitology and Mycology, Shahid Beheshti University, Tehran, Iran. 3. Dept. of Parasitology and Mycology, Gorgan University of Medical Sciences, Gorgan, Iran. 4. Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Abstract
BACKGROUND: Currently, there are no effective vaccines against leishmaniasis, and treatment using pentavalent antimonial drugs is occasionally effective and often toxic for patients. The PTR1 enzyme, which causes antifolate drug resistance in Leishmania parasites encoded by gene pteridine reductase 1 (ptr1). Since Leishmania lacks pteridine and folate metabolism, it cannot synthesize the pteridine moiety from guanine triphosphate. Therefore, it must produce pteridine using PTR1, an essential part of the salvage pathway that reduces oxidized pteridines. Thus, PTR1 is a good drug-target candidate for anti-Leishmania chemotherapy. The aim of this study was the cloning, expression, and enzymatic assay of the ptr1 gene from Iranian lizard Leishmania as a model for further studies on Leishmania. METHODS: Promastigote DNA was extracted from the Iranian lizard Leishmania, and the ptr1 gene was amplified using specific primers. The PCR product was cloned, transformed into Escherichia coli strain JM109, and expressed. The recombinant protein (PTR1 enzyme) was then purified and assayed. RESULTS: ptr1 gene was successfully amplified and cloned into expression vector. Recombinant protein (PTR1 enzyme) was purified using affinity chromatography and confirmed by Western-blot and dot blot using anti-Leishmania major PTR1 antibody and anti-T7 tag monoclonal antibody, respectively. The enzymatic assay was confirmed as PTR1 witch performed using 6-biopterin as a substrate and nicotinamide adenine dinucleotide phosphate as a coenzyme. CONCLUSION: Iranian lizard Leishmania ptr1 was expressed and enzymatic assay was performed successfully.
BACKGROUND: Currently, there are no effective vaccines against leishmaniasis, and treatment using pentavalent antimonial drugs is occasionally effective and often toxic for patients. The PTR1 enzyme, which causes antifolate drug resistance in Leishmania parasites encoded by gene pteridine reductase 1 (ptr1). Since Leishmania lacks pteridine and folate metabolism, it cannot synthesize the pteridine moiety from guanine triphosphate. Therefore, it must produce pteridine using PTR1, an essential part of the salvage pathway that reduces oxidized pteridines. Thus, PTR1 is a good drug-target candidate for anti-Leishmania chemotherapy. The aim of this study was the cloning, expression, and enzymatic assay of the ptr1 gene from Iranian lizard Leishmania as a model for further studies on Leishmania. METHODS: Promastigote DNA was extracted from the Iranian lizard Leishmania, and the ptr1 gene was amplified using specific primers. The PCR product was cloned, transformed into Escherichia coli strain JM109, and expressed. The recombinant protein (PTR1 enzyme) was then purified and assayed. RESULTS: ptr1 gene was successfully amplified and cloned into expression vector. Recombinant protein (PTR1 enzyme) was purified using affinity chromatography and confirmed by Western-blot and dot blot using anti-Leishmania major PTR1 antibody and anti-T7 tag monoclonal antibody, respectively. The enzymatic assay was confirmed as PTR1 witch performed using 6-biopterin as a substrate and nicotinamide adenine dinucleotide phosphate as a coenzyme. CONCLUSION: Iranian lizard Leishmania ptr1 was expressed and enzymatic assay was performed successfully.
Authors: Antonio Cavazzuti; Giuseppe Paglietti; William N Hunter; Francisco Gamarro; Sandra Piras; Mario Loriga; Sergio Allecca; Paola Corona; Karen McLuskey; Lindsay Tulloch; Federica Gibellini; Stefania Ferrari; Maria Paola Costi Journal: Proc Natl Acad Sci U S A Date: 2008-02-01 Impact factor: 11.205
Authors: Nafiseh Keshavarzian; Mina Noroozbeygi; Mostafa Haji Molla Hoseini; Farshid Yeganeh Journal: Front Immunol Date: 2020-10-23 Impact factor: 7.561